Start with


The RoadMap™ Analysis

The first step to coronary artery disease diagnosis.

The RoadMap Analysis provides an anatomic visualization to aid clinicians in the interpretation of CCTAs. It provides a preview of the severity and location of modeled stenoses and assists readers to:

Boost efficiency for every CCTA read1

Identify and quantify areas of narrowing2

Scale CCTA programs with consistency1

A closer look at the SMART-CT study.

Webinar: Dr. Michael Morris and Dr. Wesley O’Neal discuss insights from the SMART-CT study and its clinical implications. The study looked at the ability of the HeartFlow RoadMap Analysis in reducing CCTA interpretation time, maintaining reader accuracy and confidence, and reducing inter-reader variability.

The RoadMap Analysis overview.

Anatomy and physiology available for all CCTAs.​

Provides a preview of the severity and location of modeled stenosis

FFRCT identifies physiologically significant lesions.​

Integrate the RoadMap Analysis With ease.

workflow y.6d8577d.c9184bc00fe01e8a7903615669a1821f
flow chart
quote l
[The RoadMap Analysis] is just making reading easier. It helps me focus my search when reading the case, especially when reading a lot. I look at the RoadMap Analysis in parallel to reading [coronary CTAs] and focus mostly on capsules.

— Edward Danehy, MD
Diagnostic Radiology, Radiology Regional
quote r

Boost efficiency for every CCTA read.1

Efficiency gains realized across both Level 2 and Level 3 readers.

25 faster
efficiency gains

Identify and quantify areas of narrowing.2

high sensitivity
strong diagnostic performance

Scale CCTA programs with consistency.1

Elevate consistency across all readers for optimal patient care.

inter reader agreement

Amplify reader confidence in CCTA reads by more than 24%.3

reader condifence in study read

Value back on every CCTA.

  • Color-coded capsules closely align with CAD-RADS and indicate the location and severity of stenosis for all vessels >1.8 mm.
  • Curved planar reformation (CPR) images provided for the LAD, LCX and RCA with overlaid capsules.
  • Presence of plaque depicted on outer wall of anatomy overview image.
roadmap overview 1

Help guide treatment decisions.

  • The AHA/ACC guidelines highlight the use of FFRCT in patients with 40–90% stenosis.
  • Management plans for over 66% of patients changed after physician received the FFRCTanalysis compared to CCTA alone.4


  1. Morris, et al. A Study to Measure the Ability of AI-CSQ to support The busy CCTA reader: SMART-CT. JCCT 2023.
  2. Dundas, et al. Artificial Intelligence-based Coronary Stenosis Quantification on Coronary CT Angiography versus Quantitative Coronary Angiography. Radiology: Cardiothoracic Imaging 2023.
  3. AI Coronary Stenosis Quantifi cation on Coronary CT Angiography versus Quantitative Coronary Angiography, presented at SCCT 2023.
  4. Fairbairn, et al. Euro Heart J 2018. Patel, et al. JACC CV Imaging 2019.


Enter Your Info to View the Webinar

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.